Reversal of cisplatin resistance in vivo by an anti-fos ribozyme

Tadao Funato; Tomonori Ishii; Mariko Kanbe; Kevin J. Scanlon; Takeshi Sasaki

Reversal of cisplatin resistance in vivo by an anti-fos ribozyme

Tadao Funato, Tomonori Ishii, Mariko Kanbe, Kevin J. Scanlon, Takeshi Sasaki

Research output: Contribution to journal › Article › peer-review

Abstract

Human colon cancer cells, SW480DDP and SW620DDP, which express fos gene highly, are resistant to cisplatin treatment. We prepared a hammerhead ribozyme to selectively cleave fos mRNA and revealed that the fos ribozyme significantly suppressed the expression of fos gene in resistant cells in vitro. The fos ribozyme which was transfected into the implanted tumor cells resistant to cisplatin, had also the ability to reduce the expression of fos gene in vivo, and reversed cell sensitivity to cisplatin. These results reinforce the potential role of anti-oncogene ribozymes in dealing with the problem of drug resistance, with new possible implications for gene targetting therapy.

Original language	English
Pages (from-to)	217-220
Number of pages	4
Journal	In Vivo
Volume	11
Issue number	3
Publication status	Published - 1997
Externally published	Yes

Keywords

C-fos
Cisplatin
Colon cancer
Drug-resistance
Ribozyme

ASJC Scopus subject areas

Biochemistry, Genetics and Molecular Biology(all)
Pharmacology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{d780f161eb6e4298a56f30917bfa93a6,

title = "Reversal of cisplatin resistance in vivo by an anti-fos ribozyme",

abstract = "Human colon cancer cells, SW480DDP and SW620DDP, which express fos gene highly, are resistant to cisplatin treatment. We prepared a hammerhead ribozyme to selectively cleave fos mRNA and revealed that the fos ribozyme significantly suppressed the expression of fos gene in resistant cells in vitro. The fos ribozyme which was transfected into the implanted tumor cells resistant to cisplatin, had also the ability to reduce the expression of fos gene in vivo, and reversed cell sensitivity to cisplatin. These results reinforce the potential role of anti-oncogene ribozymes in dealing with the problem of drug resistance, with new possible implications for gene targetting therapy.",

keywords = "C-fos, Cisplatin, Colon cancer, Drug-resistance, Ribozyme",

author = "Tadao Funato and Tomonori Ishii and Mariko Kanbe and Scanlon, {Kevin J.} and Takeshi Sasaki",

year = "1997",

language = "English",

volume = "11",

pages = "217--220",

journal = "In Vivo",

issn = "0258-851X",

publisher = "International Institute of Anticancer Research",

number = "3",

}

TY - JOUR

T1 - Reversal of cisplatin resistance in vivo by an anti-fos ribozyme

AU - Funato, Tadao

AU - Ishii, Tomonori

AU - Kanbe, Mariko

AU - Scanlon, Kevin J.

AU - Sasaki, Takeshi

PY - 1997

Y1 - 1997

N2 - Human colon cancer cells, SW480DDP and SW620DDP, which express fos gene highly, are resistant to cisplatin treatment. We prepared a hammerhead ribozyme to selectively cleave fos mRNA and revealed that the fos ribozyme significantly suppressed the expression of fos gene in resistant cells in vitro. The fos ribozyme which was transfected into the implanted tumor cells resistant to cisplatin, had also the ability to reduce the expression of fos gene in vivo, and reversed cell sensitivity to cisplatin. These results reinforce the potential role of anti-oncogene ribozymes in dealing with the problem of drug resistance, with new possible implications for gene targetting therapy.

AB - Human colon cancer cells, SW480DDP and SW620DDP, which express fos gene highly, are resistant to cisplatin treatment. We prepared a hammerhead ribozyme to selectively cleave fos mRNA and revealed that the fos ribozyme significantly suppressed the expression of fos gene in resistant cells in vitro. The fos ribozyme which was transfected into the implanted tumor cells resistant to cisplatin, had also the ability to reduce the expression of fos gene in vivo, and reversed cell sensitivity to cisplatin. These results reinforce the potential role of anti-oncogene ribozymes in dealing with the problem of drug resistance, with new possible implications for gene targetting therapy.

KW - C-fos

KW - Cisplatin

KW - Colon cancer

KW - Drug-resistance

KW - Ribozyme

UR - http://www.scopus.com/inward/record.url?scp=0030834378&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030834378&partnerID=8YFLogxK

M3 - Article

C2 - 9239514

AN - SCOPUS:0030834378

SN - 0258-851X

VL - 11

SP - 217

EP - 220

JO - In Vivo

JF - In Vivo

IS - 3

ER -

Reversal of cisplatin resistance in vivo by an anti-fos ribozyme

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this